Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:15:52.726Z.
Calculation as of: 2026-10-06T15:15:52.726Z.
Quote observation: 2026-10-06T15:15:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$637.92M
Price/OCF Ratio
N/A
TTM Avg
3847.94
3Y Avg
3847.94
5Y Avg
3847.94
Market Cap
$668.72M
Price/OCF Ratio
14.49
TTM Avg
11.83
3Y Avg
25.95
5Y Avg
25.95
Market Cap
$676.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$609.03M
Price/OCF Ratio
197.16
TTM Avg
152.34
3Y Avg
179.51
5Y Avg
672.66
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $643.89M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.92M | N/A | 3847.94 | 3847.94 | 3847.94 |
| OmniAb, Inc. (OABI)vs › | $663.97M | N/A | 72.20 | 236.60 | 236.60 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $620.84M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.72M | 14.49 | 11.83 | 25.95 | 25.95 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $676.52M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $609.03M | 197.16 | 152.34 | 179.51 | 672.66 |
| Helus Pharma Inc. (HELP)vs › | $681.83M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $686.94M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.84M | 3.24 | 7.03 | 5.98 | 6.64 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
